Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • GSK Consumer...

    GSK Consumer Healthcare Q3 profit up 20 pc at Rs 163.66 cr

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-02-14T19:14:17+05:30  |  Updated On 14 Feb 2018 7:14 PM IST
    GSK Consumer Healthcare Q3 profit up 20 pc at Rs 163.66 cr

    New Delhi: GlaxoSmithKline (GSK) Consumer Healthcare Ltd today reported a 19.97 percent increase in its standalone net profit at Rs 163.66 crore for the quarter ended December 2017, on the back of a strong performance by its flagship health drink brands -- Base Horlicks and Boost.


    The company had reported a net profit of Rs 136.41 crore for the October-December period a year ago.



    Its revenue from operations stood at Rs 1,034.67 crore. It was Rs 960.17 crore in the year-ago period, GSK Consumer Healthcare said in a BSE filing.







    The company said the figure for the period up to June 30, 2017, is not relatable to those thereafter consequent to the introduction of Goods and Services Tax on July 1. Taxes such as central excise and VAT have been subsumed in GST.


    "We have delivered a strong third quarter owing to robust performances by Base Horlicks and Boost that witnessed increased market penetration and access. Our distribution for Health Food Drinks during the quarter was also amongst the best we have witnessed for some time now," GlaxoSmithKline Consumer Healthcare Managing Director Navneet Saluja said.







    "..Domestic consumer demand led by a revival in rural markets owing to the governments strong focus on rural development and higher spending on health and nutrition will create positive momentum for the sector," he added.


    Shares of GSK Consumer Healthcare today settled 1.68 per cent down at Rs 5,961 apiece on BSE

    BSEcentral exciseGlaxoSmithKlineGoods and Services TaxGSKGSK Consumer HealthcareGSThealth drink brandsHealthcareNavneet SalujaVAT
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok